Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q2 2023
Holdings as of Jun 30, 2023, filed Aug 14, 2023. Long positions only; changes compare share counts with Q1 2023.
- Positions
- 36
- −6 vs. Q1 2023
- Portfolio value
- $499.2M
- −$6.74M (−1.3%) vs. Q1 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ALPNAlpine Immune Sciences, Inc. | COM | 3,363,688 | $34.6M | 6.9% | −377,073−10.1% | Reduced | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 677,426 | $31.2M | 6.3% | 00.0% | Unchanged | History |
| PCVXVaxcyte, Inc. | COM | 589,211 | $29.4M | 5.9% | −70,000−10.6% | Reduced | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,550,184 | $28.1M | 5.6% | +338,088+27.9% | Added | History |
| RAPTRAPT Therapeutics, Inc. | COM | 1,465,151 | $27.4M | 5.5% | +110,000+8.1% | Added | History |
| PNTPOINT Biopharma Global Inc. | COM | 3,000,000 | $27.2M | 5.4% | −383,029−11.3% | Reduced | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 3,295,000 | $27.0M | 5.4% | +3,295,000 | New | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 968,795 | $20.9M | 4.2% | +185,000+23.6% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 530,000 | $20.4M | 4.1% | −288,505−35.2% | Reduced | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,941,581 | $20.1M | 4.0% | +750,000+62.9% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 600,000 | $19.6M | 3.9% | +100,000+20.0% | Added | History |
| ANABAnaptysbio, Inc | COM | 894,333 | $18.2M | 3.6% | +90,000+11.2% | Added | History |
| IMCRImmunocore Holdings plc | ADS | 297,082 | $17.8M | 3.6% | +41,715+16.3% | Added | History |
| EOLSEvolus, Inc. | COM | 2,434,048 | $17.7M | 3.5% | +241,232+11.0% | Added | History |
| JBIOJade Biosciences, Inc. | COM | 932,158 | $16.0M | 3.2% | +176,538+23.4% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 123,600 | $14.2M | 2.8% | +123,600 | New | History |
| ALKSAlkermes plc. | SHS | 411,453 | $12.9M | 2.6% | +411,453 | New | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 772,000 | $12.7M | 2.6% | +674,456+691.4% | Added | History |
| OPTNOptiNose, Inc. | COM | 8,839,939 | $10.9M | 2.2% | +945,203+12.0% | Added | History |
| VKTXViking Therapeutics, Inc. | COM | 598,550 | $9.70M | 1.9% | −401,450−40.1% | Reduced | History |
| MLYSMineralys Therapeutics, Inc. | COM | 546,059 | $9.31M | 1.9% | −74,267−12.0% | Reduced | History |
| FOLDAmicus Therapeutics, Inc. | COM | 701,392 | $8.81M | 1.8% | +321,392+84.6% | Added | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 2,268,057 | $8.64M | 1.7% | −885,149−28.1% | Reduced | – |
| OKUROnKure Therapeutics, Inc. | COM | 1,083,317 | $7.11M | 1.4% | +962,453+796.3% | Added | History |
| ICPTIntercept Pharmaceuticals, Inc. | COM | 601,322 | $6.65M | 1.3% | +601,322 | New | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 350,000 | $6.32M | 1.3% | +350,000 | New | History |
| GBIOGeneration Bio Co. | COM | 1,022,537 | $5.62M | 1.1% | 00.0% | Unchanged | History |
| HRTXHeron Therapeutics, Inc. | COM | 4,737,368 | $5.50M | 1.1% | −1,080,000−18.6% | Reduced | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 1,051,267 | $5.06M | 1.0% | 00.0% | Unchanged | History |
| IGMSIGM Biosciences, Inc. | COM | 500,000 | $4.62M | 0.9% | +500,000 | New | History |
| MCRBSeres Therapeutics, Inc. | COM | 938,067 | $4.49M | 0.9% | +938,067 | New | History |
| DTILPrecision Biosciences Inc | COM | 7,469,736 | $3.93M | 0.8% | −630,063−7.8% | Reduced | History |
| SLDBSolid Biosciences Inc. | COM NEW | 584,458 | $3.06M | 0.6% | +374,053+177.8% | Added | History |
| TRMLTourmaline Bio, Inc. | COM | 666,033 | $2.02M | 0.4% | +666,033 | New | History |
| ACLXArcellx, Inc. | COMMON STOCK | 37,500 | $1.19M | 0.2% | −219,506−85.4% | Reduced | History |
| TVTXTravere Therapeutics, Inc. | COM | 60,000 | $921.6K | 0.2% | −943,000−94.0% | Reduced | History |
Options (4)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q1 2023 (14)
Positions held at the end of Q1 2023 that are gone from this filing.
| Security | Class | Shares in Q1 2023 | Value in Q1 2023 | % of portfolio in Q1 2023 | History |
|---|---|---|---|---|---|
| JAZZJazz Pharmaceuticals plc | SHS USD | 149,500 | $21.9M | 4.3% | History |
| ISEEIVERIC bio, Inc. | COM | 694,009 | $16.9M | 3.3% | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,600,545 | $12.6M | 2.5% | History |
| RLAYRelay Therapeutics, Inc. | COM | 658,127 | $10.8M | 2.1% | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 278,334 | $5.95M | 1.2% | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 507,500 | $4.43M | 0.9% | History |
| LRMRLarimar Therapeutics, Inc. | COM | 900,000 | $4.08M | 0.8% | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 70,371 | $3.81M | 0.8% | History |
| ETNB89bio, Inc. | COM | 250,000 | $3.81M | 0.8% | History |
| ZVRAZevra Therapeutics, Inc. | COM NEW | 347,824 | $1.91M | 0.4% | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 141,526 | $1.89M | 0.4% | History |
| PRAXPraxis Precision Medicines, Inc. | COM | 2,032,550 | $1.64M | 0.3% | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 474,639 | $830.6K | 0.2% | History |
| URGNUroGen Pharma Ltd. | COM | 39,222 | $362.4K | 0.1% | History |